Nakagawa T - Search Results

1

Effects of keishibukuryogan on vascular function in adjuvant-induced arthritis rats.

Nozaki K, Goto H, Nakagawa T, Hikiami H, Koizumi K, Shibahara N, Shimada Y. Nozaki K, et al. Among authors: nakagawa t. Biol Pharm Bull. 2007 Jun;30(6):1042-7. doi: 10.1248/bpb.30.1042. Biol Pharm Bull. 2007. PMID: 17541151 Free article.

2

Oren-gedoku-to and Keishi-bukuryo-gan-ryo inhibit the progression of atherosclerosis in diet-induced hypercholesterolemic rabbits.

Sekiya N, Kainuma M, Hikiami H, Nakagawa T, Kouta K, Shibahara N, Shimada Y, Terasawa K. Sekiya N, et al. Among authors: nakagawa t. Biol Pharm Bull. 2005 Feb;28(2):294-8. doi: 10.1248/bpb.28.294. Biol Pharm Bull. 2005. PMID: 15684487 Free article.

3

Expression patterns of plasma proteins in spontaneously diabetic rats after oral administration of a Kampo medicine, Hachimi-jio-gan, using SELDI ProteinChip platform.

Kiga C, Nakagawa T, Koizumi K, Sakurai H, Shibagaki Y, Ogawa K, Goto H, Saiki I. Kiga C, et al. Among authors: nakagawa t. Biol Pharm Bull. 2005 Jun;28(6):1031-7. doi: 10.1248/bpb.28.1031. Biol Pharm Bull. 2005. PMID: 15930740 Free article.

4

Keishibukuryogan (gui-zhi-fu-ling-wan), a Kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis.

Nozaki K, Hikiami H, Goto H, Nakagawa T, Shibahara N, Shimada Y. Nozaki K, et al. Among authors: nakagawa t. Evid Based Complement Alternat Med. 2006 Sep;3(3):359-64. doi: 10.1093/ecam/nel025. Evid Based Complement Alternat Med. 2006. PMID: 16951720 Free PMC article.

5

Protective effects of keishibukuryogan on the kidney of spontaneously diabetic WBN/Kob rats.

Nakagawa T, Goto H, Hikiami H, Yokozawa T, Shibahara N, Shimada Y. Nakagawa T, et al. J Ethnopharmacol. 2007 Mar 21;110(2):311-7. doi: 10.1016/j.jep.2006.09.043. Epub 2006 Oct 18. J Ethnopharmacol. 2007. PMID: 17123761

6

Cinnamaldehyde induces endothelium-dependent and -independent vasorelaxant action on isolated rat aorta.

Yanaga A, Goto H, Nakagawa T, Hikiami H, Shibahara N, Shimada Y. Yanaga A, et al. Among authors: nakagawa t. Biol Pharm Bull. 2006 Dec;29(12):2415-8. doi: 10.1248/bpb.29.2415. Biol Pharm Bull. 2006. PMID: 17142974 Free article.

7

Keishibukuryogan ameliorates glucose intolerance and hyperlipidemia in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.

Nakagawa T, Goto H, Hussein G, Hikiami H, Shibahara N, Shimada Y. Nakagawa T, et al. Diabetes Res Clin Pract. 2008 Apr;80(1):40-7. doi: 10.1016/j.diabres.2007.11.019. Epub 2008 Feb 1. Diabetes Res Clin Pract. 2008. PMID: 18242756

8

Long-term treatment with Hachimi-jio-gan attenuates kidney damage in spontaneously diabetic WBN/Kob rats.

Nakagawa T, Yokozawa T, Yamabe N, Rhyn DY, Goto H, Shimada Y, Shibahara N. Nakagawa T, et al. J Pharm Pharmacol. 2005 Sep;57(9):1205-12. doi: 10.1211/jpp.57.9.0016. J Pharm Pharmacol. 2005. PMID: 16105242

9

Protective effects of gamma-aminobutyric acid in rats with streptozotocin-induced diabetes.

Nakagawa T, Yokozawa T, Kim HJ, Shibahara N. Nakagawa T, et al. J Nutr Sci Vitaminol (Tokyo). 2005 Aug;51(4):278-82. doi: 10.3177/jnsv.51.278. J Nutr Sci Vitaminol (Tokyo). 2005. PMID: 16262002

10

Keishibukuryogan reduces renal injury in the early stage of renal failure in the remnant kidney model.

Nakagawa T, Tashiro I, Fujimoto M, Jo M, Sakai S, Oka H, Goto H, Shimada Y, Shibahara N. Nakagawa T, et al. Evid Based Complement Alternat Med. 2011;2011:914249. doi: 10.1093/ecam/nep089. Epub 2011 May 3. Evid Based Complement Alternat Med. 2011. PMID: 19633031 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,389 results

Search Page

Filters